RET and medullary thyroid gland carcinoma: Until now the only approved treatments for MTC are radiotherapy, surgical resection, RET inhibitors (e.g., selpercatinib and pralsetinib), or targeting downstream proteins in the RET-mediated signaling, such as RAS (54).